All In MedTech

Device Trial Radar · NCT06464926

Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System (NAVIGATE)

A Prospective Randomized Controlled Trial of Chronic Nausea and Vomiting in Patients With Normal Gastric Emptying Using the Enterra® Therapy System

Last checked: Nov 21, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 148 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

148

Planned (sponsor's estimate)

Start

Jun 23, 2025

Primary completion

Jun 2030

Study completion Jun 2030

Sponsor

Lead sponsor
Enterra Medical, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Bright Research Partners
First posted
Jun 18, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to determine if the Enterra® Therapy System can decrease nausea and vomiting symptoms and improve the quality of life for patients with chronic nausea, with or without vomiting, that have normal gastric emptying.

Conditions

  • Nausea
  • Vomiting

Interventions

  • Enterra Therapy SystemDevice

    The Enterra Therapy System is a gastric electrical stimulator system consisting of an implantable pulse generator (Enterra II Model 37800 neurostimulator); two implantable unipolar leads (Enterra Model 4351-35 intramuscular); and device programmer (N'Vision Clinician Programmer Model 8840 with Model 8870 Application Card). The programmable neurostimulator operates on a sealed battery and electronic circuitry to provide controlled electrical pulse stimulation through the implanted lead system. A clinician programmer is used to program the neurostimulator and adjust stimulation settings to programmable parameters and stimulation options.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Nausea Severity ScoreTime frame: 4 Months

Locations

22 sites in 5 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Scottsdale, Arizona · Recruiting

21 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.